Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
University of Chicago · Kanagawa Prefectural Hospital Organization · +16 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
219
total citations
- FWCI
- 54.90
- Percentile
- 100%
- References
- 25
Citations per year
Authors
274Topics & keywords
Topics
Keywords
- Pembrolizumab
- Medicine
- Chemotherapy
- Oncology
- Stage (stratigraphy)
- Internal medicine
- Lung cancer
- Adjuvant
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- AAmgen
- BSBristol-Myers Squibb
- ELEli Lilly and Company
- PPfizerAward: P30 CA008748
- AAstraZeneca
- GGlaxoSmithKline
- SSanofi
- GSGilead Sciences
- CCelgene
- HHelsinn
- RPRegeneron Pharmaceuticals
- MKMerck KGaA
- BBeiGene
- IIncyte
- SSeagen
- DDaiichi-SankyoAward: P30 CA008748
- EEisaiAward: P30 CA008748
- NINational Institutes of HealthAward: P30 CA008748
- GGenentechAward: P30 CA008748
- CPChugai Pharmaceutical